These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25081431)

  • 1. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease.
    Thimonier E; Guillaud O; Walter T; Decullier E; Vallin M; Boillot O; Dumortier J
    Clin Transplant; 2014 Dec; 28(12):1339-48. PubMed ID: 25081431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center.
    Dumortier J; Guillaud O; Adham M; Boucaud C; Delafosse B; Bouffard Y; Paliard P; Scoazec JY; Boillot O
    Am J Gastroenterol; 2007 May; 102(5):1032-41. PubMed ID: 17313502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients.
    Vallin M; Guillaud O; Morard I; Gagnieu MC; Mentha G; Adham M; Morelon E; Boillot O; Giostra E; Dumortier J
    Clin Transplant; 2011; 25(4):660-9. PubMed ID: 21158921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indications and management of everolimus after liver transplantation.
    Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
    Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
    Jiménez-Romero C; Manrique A; Marqués E; Calvo J; Sesma AG; Cambra F; Abradelo M; Sterup RM; Olivares S; Justo I; Colina F; Moreno E
    Hepatogastroenterology; 2011; 58(105):115-21. PubMed ID: 21510297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease.
    Dumortier J; Maucort-Boulch D; Poinsot D; Thimonier E; Chambon-Augoyard C; Ducroux E; Vallin M; Walter T; Robinson P; Guillaud O; Boillot O
    Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):427-435. PubMed ID: 29861393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
    Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
    Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo esophageal neoplasia after liver transplantation.
    Presser SJ; Schumacher G; Neuhaus R; Thuss-Patience P; Stieler J; Neuhaus P
    Liver Transpl; 2007 Mar; 13(3):443-50. PubMed ID: 17318861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of upper aerodigestive tract cancer after liver transplantation for alcoholic cirrhosis: a 10-year experience in an Italian center.
    Nure E; Frongillo F; Lirosi MC; Grossi U; Sganga G; Avolio AW; Siciliano M; Addolorato G; Mariano G; Agnes S
    Transplant Proc; 2013 Sep; 45(7):2733-5. PubMed ID: 24034035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
    Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
    Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database.
    Singal AK; Bashar H; Anand BS; Jampana SC; Singal V; Kuo YF
    Hepatology; 2012 May; 55(5):1398-405. PubMed ID: 22213344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases.
    Jiménez-Romero C; Manrique Municio A; Marqués Medina E; Colina F; Ortega Domene P; Gómez Sanz R; Meneu Diaz JC; Abradelo de Usera M; Moreno Elola A; Moreno Gonzalez E
    Transplant Proc; 2006 Oct; 38(8):2505-7. PubMed ID: 17097982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis.
    Baur B; Oroszlan M; Hess O; Carrel T; Mohacsi P
    Transplant Proc; 2011 Jun; 43(5):1853-61. PubMed ID: 21693289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.
    Aguilera V; Berenguer M; Rubín A; San-Juan F; Rayón JM; Prieto M; Mir J
    Liver Transpl; 2009 Jan; 15(1):79-87. PubMed ID: 19109849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after liver transplantation for cirrhosis due to alcohol and hepatitis C: comparison to alcoholic cirrhosis and hepatitis C cirrhosis.
    Singal AK; Hmoud BS; Guturu P; Kuo YF
    J Clin Gastroenterol; 2013 Sep; 47(8):727-33. PubMed ID: 23751845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients.
    Sérée O; Altieri M; Guillaume E; De Mil R; Lobbedez T; Robinson P; Segol P; Salamé E; Abergel A; Boillot O; Conti F; Chazouillères O; Debette-Gratien M; Debray D; Hery G; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Jacquemin E; Kamar N; Latournerie M; Lebray P; Leroy V; Mazzola A; Neau-Cransac M; Pageaux GP; Radenne S; Saliba F; Samuel D; Vanlemmens C; Woehl-Jaegle ML; Launoy G; Dumortier J
    Liver Transpl; 2018 Oct; 24(10):1425-1436. PubMed ID: 30021061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo malignancies following liver transplantation: a case-control study with long-term follow-up.
    Yao FY; Gautam M; Palese C; Rebres R; Terrault N; Roberts JP; Peters MG
    Clin Transplant; 2006; 20(5):617-23. PubMed ID: 16968488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.